Otilonium bromide
Otilonium bromide is an antimuscarinic and calcium channel blocker used to relieve spasmodic pain of the gut, especially in irritable bowel syndrome.[1]
Clinical data | |
---|---|
Trade names | Spasmoctyl 40, Doralin |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
IUPAC name
| |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.043.128 |
Chemical and physical data | |
Formula | C29H43BrN2O4 |
Molar mass | 563.57 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
|
Medical uses
A pooled analysis of three clinical trials suggest that otilonium is more effective than placebo for the treatment of irritable bowel syndrome.[2]
Pharmacology
Otilinium binds to both muscarinic receptors and tachykinin NK2 receptors.[3] It has been shown to inhibit L-type and T-type calcium channels, actions which may contribute to or determine its effects in the gut.[4][5]
When taken orally, very little of the drug is absorbed into the rest of the body,[6] which means that most of its actions remain confined to the gastrointestinal system.
References
- "Dismox" (PDF). Archived from the original (PDF) on 4 March 2016.
- Clavé, P; Tack, J (March 2017). "Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis". Therapeutic advances in gastroenterology. 10 (3): 311–322. doi:10.1177/1756283X16681708. PMC 5305018. PMID 28246548.
- Evangelista, S (1999). "Otilonium bromide: a selective spasmolytic for the gastrointestinal tract". The Journal of international medical research. 27 (5): 207–22. doi:10.1177/030006059902700501. PMID 10689627.
- Martin, MT; Hove-Madsen, L; Jimenez, M (April 2004). "Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon". Neurogastroenterology & Motility. 16 (2): 175–83. doi:10.1111/j.1365-2982.2004.00518.x. PMID 15086871.
- Strege, PR; Sha, L; Beyder, A; Bernard, CE; Perez-Reyes, E; Evangelista, S; Gibbons, SJ; Szurszewski, JH; Farrugia, G (May 2010). "T-type Ca(2+) channel modulation by otilonium bromide". American Journal of Physiology. Gastrointestinal and Liver Physiology. 298 (5): G706–13. doi:10.1152/ajpgi.00437.2009. PMC 2867415. PMID 20203058.
- Shin, BS; Kim, JJ; Kim, J; Hu, SK; Kim, HJ; Hong, SH; Kim, HK; Lee, HS; Yoo, SD (January 2008). "Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats". Archives of Pharmacal Research. 31 (1): 117–24. doi:10.1007/s12272-008-1129-2. PMID 18277617.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.